Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose
22153
Phase 3 small_molecule completed
Quick answer
Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose for Macular Edema Secondary to Retinal Vein Occlusion is a Phase 3 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- Macular Edema Secondary to Retinal Vein Occlusion
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed